![Text that says Results](/sites/default/files/styles/square_card_l/public/media/images/media-71.jpg.webp?itok=UNXuLIDJ)
Encouraging initial results for newer drugs to treat diffuse large B-cell lymphoma
MOR2018 and lenalidomide could be a new treatment combination for diffuse large B-cell lymphoma (DLBCL) that has relapsed (come back) or was refractory (didn’t respond well) to previous treatment.